Johns Hopkins Develops Precision Antibody-Drug Conjugate for TRBC2-Positive T-Cell Cancers
核心洞察
Johns Hopkins researchers developed JX1.1 (搜索), a novel antibody-drug conjugate targeting TRBC2 (搜索)-positive T-cell cancers, completing a precision therapy approach for T-cell malignancies.
The therapy demonstrated complete tumor elimination in animal models over 150 days while preserving 40-60% of normal T cells, addressing a critical safety challenge in T-cell cancer treatment.
This breakthrough provides therapeutic options for approximately half of T-cell lymphoma and leukemia patients who express TRBC2 (搜索) variants, addressing an unmet medical need in rare cancers with poor survival rates.
Researchers at the Johns Hopkins Kimmel Cancer Center (搜索)'s Ludwig Center (搜索) have developed a groundbreaking antibody-drug conjugate (ADC) that selectively targets TRBC2 (搜索)-positive T-cell cancers, providing a precision therapeutic approach for approximately half of patients with T-cell lymphomas (搜索) and leukemias. The work, published December 22 in Nature Cancer, completes a matched set of precision tools that the team began developing in 2024 with their TRBC1 (搜索)-targeting therapy.
Addressing Critical Unmet Medical Need
T-cell lymphomas (搜索) and leukemias affect roughly 100,000 people worldwide each year, representing rare and scientifically complex malignancies that have received significantly less pharmaceutical investment than B-cell cancers. Adults with relapsed T-cell cancers face particularly grim prospects, with five-year survival rates ranging from just 7% to 38%.
"There is a challenging situation," explains senior author Suman Paul, M.B.B.S., Ph.D., assistant professor of oncology, "because unlike B-cell therapies — where eliminating both cancerous and healthy B cells is tolerable — therapies targeting T cells must preserve enough normal T cells for patients to survive infections."
The fundamental challenge lies in the delicate balance required for T-cell targeted therapies. "The tricky part is that if the drug kills both the T-cell lymphoma and the normal T cells, then it's very hard for that person to survive," Paul explains. "We have to be mindful that it has to get rid of the cancer, but it cannot completely get rid of the normal T cells."
Precision Targeting Strategy
The Johns Hopkins team's solution centers on targeting TRBC1 (搜索) or TRBC2 (搜索), two mutually exclusive genetic variants of the T-cell receptor. Normal T cells comprise a mix of TRBC1-positive (~40%) and TRBC2-positive (~60%) populations, but each T-cell cancer expresses only one of the two variants. This biological characteristic enables selective targeting of the cancer-associated TRBC variant while preserving approximately 40-60% of normal T cells.
While the team published findings on the first TRBC1 (搜索)-targeting therapeutic antibody in 2024, no TRBC2 (搜索)-specific therapeutic antibody existed until now, leaving half of T-cell cancer patients without an equivalent precision approach.
Novel Antibody Development
To create the TRBC2 (搜索)-targeting therapy, researchers employed a phage-displayed antibody library to develop JX1.1 (搜索), a new antibody that recognizes only the TRBC2 protein target while avoiding the similar TRBC1 (搜索) protein.
"Our antibody was developed using SLISY, a next-generation sequencing-based platform for rapid identification of antibody candidates from a phage library," says Ken Kinzler, Ph.D., Barry Family Professor in Oncology and director of the Ludwig Center (搜索).
The team then linked the JX1.1 (搜索) antibody to pyrrolobenzodiazepine (搜索), a cancer cell-killing drug, to generate the final antibody-drug conjugate.
Preclinical Efficacy and Safety
Laboratory studies using cancer cell lines and animal models demonstrated the ADC's high specificity for TRBC2 (搜索) cancers, with clear discrimination between TRBC2-positive and TRBC1 (搜索)-positive normal T cells. The therapy killed TRBC2-positive cancer cells and achieved robust tumor regression in animal models with minimal toxicity.
Remarkably, all JX1.1 (搜索)-treated mice sustained complete elimination of detectable cancer throughout the entire 150-day follow-up period, demonstrating both the therapy's efficacy and durability.
Clinical Implications
"The development of TRBC1 (搜索) and TRBC2 (搜索) antibodies together now provides a conceptual 'matched set' of precision tools for the great majority of patients with T-cell cancers," says Paul.
This breakthrough represents a significant advancement in precision oncology for T-cell malignancies, offering hope for patients with limited therapeutic options. The complementary TRBC1 (搜索) and TRBC2 (搜索) targeting approaches now provide coverage for the vast majority of T-cell cancer patients, potentially transforming treatment outcomes in this challenging disease area.
The research involved an extensive collaborative team and received support from multiple funding sources, including the Virginia and D.K. Ludwig Fund for Cancer Research, National Institutes of Health grants, and various cancer research foundations.